FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Company

AIPING PHARM INC.

Pharmaceutical intelligence for AIPING PHARM INC. with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

RegulatoryAugust 17, 2026

FDA Approval Status for Haloperidol ANDA071130 by AIPING PHARM INC.

The FDA has an active application (ANDA071130) for Haloperidol submitted by AIPING PHARM INC., currently under AP status. This application indicates that AIPING PHARM INC. is seeking to introduce a generic version of Haloperidol, a well-established antipsychotic medication.